NICE Opens Door to Axhidrox Cream

2026-10-15

Severe underarm sweating deserves more than cosmetic dismissal: NICE will recommend Axhidrox, the first licensed topical treatment for severe primary axillary hyperhidrosis in adults, as an option. That distinction matters clinically. The glycopyrronium cream offers a treatment directed at sweat production, rather than an attempt to disguise its visible consequences.

The appeal lies in precision, not novelty alone: glycopyrronium is an anticholinergic that blocks muscarinic acetylcholine receptors, reducing the stimulation of eccrine sweat glands. The target is specific. In primary axillary hyperhidrosis, underarm sweating exceeds what the body needs for temperature regulation, without an underlying disease explaining it. Daily life can shrink. Clothing choices, work encounters and social confidence may all become negotiations with perspiration, which helps explain why a licensed cream can carry significance beyond the bathroom shelf. Yet reducing sweat is not the same as removing the condition's every burden.

A recommendation is progress, not a promise that every patient should receive the same prescription: licensing establishes an authorised use, while NICE guidance informs treatment choices within the health service. Suitability still needs assessment. Anticholinergic effects can include dry mouth and visual disturbances, and precautions remain relevant even when a medicine is applied to the skin. Expectations need discipline too. The announcement does not establish that Axhidrox outperforms every alternative, nor does it make treatment selection automatic; the decision belongs in a clinical discussion about symptoms, risks and preferences. Behind the prescription sits a modest ambition: a shirt chosen without calculation.

Recommendations